Trial Profile
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Apr 2021 A population pharmacokinetic model was developed for sunitinib and SU012662 in pediatric patients with GIST or other solid tumors, results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 04 Oct 2017 Status changed from recruiting to completed.
- 13 Sep 2017 The study has been been completed in Hungary (End date: 2017-08-21)